Opus Genetics, Inc. (IRD) Financial Analysis & Valuation | Quarter Chart
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as we... more
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing an... more
Company facts
Reported company information and share structure.
Company
Share structure
| Market Cap | $288.69M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | George Magrath |
| IPO Date | 2015-01-19 | CAGR | — |
| Employees | 28 | Website | opusgtx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.01% | Total Yield | 0.01% |
IRD chart loading...
Key metrics
Reported fundamentals and market-derived technical indicators.
Fundamentals
Technicals
| EV | $326.29M | P/E | -2.71 | Forward P/E | -4.85 | PEG | — |
| P/S | 555717.91 | P/B | -487494.28 | P/CF | -118814.09 | P/FCF | -102825.67 |
| Sales | $9.86M | Sales 1Y | -36.09% | Sales 3Y | -78.23% | Sales 5Y | 9756% |
| EPS | $-1.28 | EPS 1Y | -24.43% | EPS 3Y | -258.33% | EPS 5Y | -80.06% |
| Sales QoQ | -65% | EPS QoQ | -81.33% | Sales QoQ Avg | -19.21% | EPS QoQ Avg | 74.43% |
| Gross Margin | 99.87% | Operating Margin | -513.47% | Profit Margin | -1091.82% | ROCE | -59.29% |
| ROA | -116% | ROE | 1148% | Altman Z Score | -4.8 | Piotroski Score | 3 |
| Current Ratio | 12.19 | Quick Ratio | 12.19 | Cash Ratio | 11.68 | Op. CF Ratio | -3.24 |
| Debt/Equity | -2.69 | Debt/Assets | 0.38 | Lt Debt/Equity | -2.69 | Lt Debt/Cap. | 1.59 |
| Intrst Cov. | -19.11 | Inventory Turnover | — | Asset Turnover | 0.11 | Receivables Turnover | 6.77 |
| Enterprise Value | $326.29M | P/E Ratio | -2.71 |
| Forward P/E | -4.85 | PEG Ratio | — |
| P/S Ratio | 555717.91 | P/B Ratio | -487494.28 |
| P/CF Ratio | -118814.09 | P/FCF Ratio | -102825.67 |
| EPS | $-1.28 | EPS Growth 1Y | -24.43% |
| EPS Growth 3Y | -258.33% | EPS Growth 5Y | -80.06% |
| Revenue Growth 1Y | -36.09% | Gross Margin | 99.87% |
| Operating Margin | -513.47% | Profit Margin | -1091.82% |
| ROE | 1148% | ROA | -116% |
| ROCE | -59.29% | Current Ratio | 12.19 |
| Quick Ratio | 12.19 | Cash Ratio | 11.68 |
| Debt/Equity | -2.69 | Interest Coverage | -19.11 |
| Altman Z Score | -4.8 | Piotroski Score | 3 |
Opus Genetics, Inc. (IRD) valuation & financials
Opus Genetics, Inc. (IRD) has a market capitalization of $288.69M and trades at a price-to-earnings ratio of -2.7. It operates in the Healthcare sector (Biotechnology).
Opus Genetics, Inc.'s revenue grew -36.1% over the last year.
Opus Genetics, Inc.'s next earnings report is scheduled for November 11, 2026 (provider scheduled date); analysts estimate EPS of $-0.14. Check the earnings calendar to see all companies reporting this week.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)